SMYD3 and neoplasm: These findings demonstrate that Smyd3 and Shcbp1 are dominant oncogenic drivers and that silencing Smyd3 and Shcbp1 in epithelial cells could minimize tumor growth and block their negative effect on abnormal immune responses in spleen tissues in mice.